相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Julie R. Gralow et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
Ulrike Nitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
Manuel Ruiz-Borrego et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial
Timothy J. Whelan et al.
LANCET (2019)
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni et al.
LANCET ONCOLOGY (2018)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2018)
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Kathy D. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
R. Bell et al.
ANNALS OF ONCOLOGY (2017)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L. Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Cyclophosphamide and DocetaxelWith or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
Bent Ejlertsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
Charlotte E. Coles et al.
LANCET (2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin et al.
LANCET ONCOLOGY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant treatment of HER2-positive early breast cancer
Alvaro Moreno-Aspitia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery
E. Botteri et al.
BRITISH JOURNAL OF SURGERY (2017)
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
Richard G. Margolese et al.
LANCET (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Joyce O'Shaughnessy et al.
CLINICAL CANCER RESEARCH (2015)
Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial
Lorenzo Livi et al.
EUROPEAN JOURNAL OF CANCER (2015)
RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation
Beryl McCormick et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Miguel Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008
Rachel J. D. Cossetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study
Lawrence J. Solin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
George T. Budd et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
Ian H. Kunkler et al.
LANCET ONCOLOGY (2015)
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
Lawrence N. Shulman et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Mila Donker et al.
LANCET ONCOLOGY (2014)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial
Sandra M. Swain et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Kevin S. Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H. G. Paterson et al.
LANCET ONCOLOGY (2012)
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
Debora Fumagalli et al.
LANCET ONCOLOGY (2012)
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag et al.
LANCET ONCOLOGY (2010)
Pathobiology of small invasive breast cancers without Metastases (T1a/b, N0, M0) - National surgical adjuvant breast and bowel project (NSABP) protocol B-21
Edwin R. Fisher et al.
CANCER (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
KS Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
